Andy Hsieh
Stock Analyst at William Blair
(4.33)
# 1,349
Out of 4,707 analysts
355
Total ratings
48.7%
Success rate
9.6%
Average return
Main Sectors:
Stocks Rated by Andy Hsieh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GPCR Structure Therapeutics | Reiterated: Buy | n/a | $40.38 | - | 12 | Sep 8, 2026 | |
| KYNB Kyntra Bio | Reiterated: Hold | n/a | $8.22 | - | 29 | Aug 31, 2026 | |
| ELVN Enliven Therapeutics | Maintained: Buy | n/a | $59.37 | - | 2 | Aug 22, 2026 | |
| NKTR Nektar Therapeutics | Maintained: Buy | n/a | $75.44 | - | 31 | Aug 14, 2026 | |
| PYXS Pyxis Oncology | Maintained: Hold | n/a | $3.89 | - | 11 | Aug 13, 2026 | |
| ALT Altimmune | Reiterated: Hold | n/a | $3.36 | - | 12 | Aug 12, 2026 | |
| AVIR Atea Pharmaceuticals | Reiterated: Buy | n/a | $5.68 | - | 11 | Aug 12, 2026 | |
| AARD Aardvark Therapeutics | Reiterated: Buy | n/a | $5.33 | - | 6 | Aug 12, 2026 | |
| KLRA Kailera Therapeutics | Maintained: Buy | n/a | $16.43 | - | 5 | Aug 12, 2026 | |
| CRDF Cardiff Oncology | Downgraded: Hold | n/a | $1.10 | - | 18 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $100.44 | - | 18 | Aug 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $57.67 | - | 59 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $10.60 | - | 16 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $9.40 | - | 14 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $33.68 | - | 39 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $0.6634 | - | 5 | Jul 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $1.88 | - | 17 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $46.61 | - | 3 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $0.7401 | n/a | 9 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.23 | n/a | 15 | Dec 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.6202 | n/a | 22 | Dec 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $146.64 | n/a | 1 | Feb 12, 2019 |
Structure Therapeutics
Sep 8, 2026
Reiterated: Buy
Price Target: n/a
Current: $40.38
Upside: -
Kyntra Bio
Aug 31, 2026
Reiterated: Hold
Price Target: n/a
Current: $8.22
Upside: -
Enliven Therapeutics
Aug 22, 2026
Maintained: Buy
Price Target: n/a
Current: $59.37
Upside: -
Nektar Therapeutics
Aug 14, 2026
Maintained: Buy
Price Target: n/a
Current: $75.44
Upside: -
Pyxis Oncology
Aug 13, 2026
Maintained: Hold
Price Target: n/a
Current: $3.89
Upside: -
Altimmune
Aug 12, 2026
Reiterated: Hold
Price Target: n/a
Current: $3.36
Upside: -
Atea Pharmaceuticals
Aug 12, 2026
Reiterated: Buy
Price Target: n/a
Current: $5.68
Upside: -
Aardvark Therapeutics
Aug 12, 2026
Reiterated: Buy
Price Target: n/a
Current: $5.33
Upside: -
Kailera Therapeutics
Aug 12, 2026
Maintained: Buy
Price Target: n/a
Current: $16.43
Upside: -
Cardiff Oncology
Aug 11, 2026
Downgraded: Hold
Price Target: n/a
Current: $1.10
Upside: -
Aug 8, 2026
Reiterated: Hold
Price Target: n/a
Current: $100.44
Upside: -
Aug 6, 2026
Maintained: Buy
Price Target: n/a
Current: $57.67
Upside: -
Aug 6, 2026
Reiterated: Buy
Price Target: n/a
Current: $10.60
Upside: -
Aug 6, 2026
Reiterated: Hold
Price Target: n/a
Current: $9.40
Upside: -
Jul 30, 2026
Reiterated: Buy
Price Target: n/a
Current: $33.68
Upside: -
Jul 29, 2026
Maintained: Buy
Price Target: n/a
Current: $0.6634
Upside: -
May 12, 2026
Reiterated: Buy
Price Target: n/a
Current: $1.88
Upside: -
Mar 6, 2026
Downgraded: Hold
Price Target: n/a
Current: $46.61
Upside: -
Aug 7, 2025
Reiterated: Buy
Price Target: n/a
Current: $0.7401
Upside: n/a
Dec 22, 2023
Rated: Hold
Price Target: n/a
Current: $1.23
Upside: n/a
Dec 1, 2021
Downgraded: Hold
Price Target: n/a
Current: $0.6202
Upside: n/a
Feb 12, 2019
Maintained: Buy
Price Target: n/a
Current: $146.64
Upside: n/a